Nursing Elites

1. A client has a new prescription for Labetalol. Which of the following instructions should be provided?

• A. Take the medication with food.
• B. Monitor your blood glucose levels.
• C. Expect a rapid heart rate.
• D. Increase your intake of high-sodium foods.

Correct answer: A

Rationale: The correct answer is A: Take the medication with food. Labetalol should be taken with food to increase absorption and reduce the risk of orthostatic hypotension. Taking it with food helps in better absorption and minimizes the potential drop in blood pressure when standing up, which can occur with this medication. Choice B is incorrect as Labetalol is not primarily associated with affecting blood glucose levels. Choice C is incorrect as Labetalol is a beta-blocker that would actually lower heart rate, not increase it. Choice D is incorrect because increasing intake of high-sodium foods could counteract the antihypertensive effects of Labetalol.

2. A client is receiving discharge instructions for long-term use of Prednisone. Which of the following instructions should be included?

• A. Stop taking the medication if you experience swelling.
• B. The provider will monitor your weight regularly.
• C. Take the medication on an empty stomach.
• D. You may notice decreased appetite while on this medication.

Correct answer: B

Rationale: The correct answer is B because long-term use of Prednisone can lead to weight gain, necessitating regular weight monitoring by the healthcare provider to manage any potential complications. Prednisone often causes fluid retention, leading to weight gain, hence the need for weight monitoring. Options A, C, and D are incorrect because swelling is not a typical reason to stop Prednisone, taking it on an empty stomach is not usually required, and Prednisone commonly increases appetite rather than decreases it.

3. A client receives a new prescription for NRTIs for HIV treatment. Which statement should the nurse include during teaching about these medications?

• A. These medications work by inhibiting enzymes to prevent HIV replication.
• B. These medications work by preventing protein synthesis within the HIV cell.
• C. These medications work by weakening the cell wall of the HIV virus.
• D. These medications work by blocking HIV entry into cells.

Correct answer: A

Rationale: NRTIs inhibit the enzyme reverse transcriptase, essential for HIV replication. By preventing this process, viral replication is hindered, ultimately reducing the viral load in the body. Option A correctly explains the mechanism of action of NRTIs in treating HIV infection. Choices B, C, and D describe mechanisms of action that do not align with how NRTIs work in HIV treatment. B is incorrect because NRTIs do not target protein synthesis within the HIV cell. C is incorrect as NRTIs do not affect the cell wall of the HIV virus. D is incorrect because NRTIs do not block HIV entry into cells.

4. Which of the following conditions is not treated with Prednisone?

• A. Cushing’s disease
• B. Testicular cancer
• C. Lymphomas
• D. Chronic leukemias

Correct answer: B

Rationale: Prednisone is not a common treatment for testicular cancer. Prednisone is used in conditions like Cushing’s disease, lymphomas, and chronic leukemias due to its anti-inflammatory and immunosuppressive properties. However, testicular cancer treatment typically involves surgery, chemotherapy, and radiation therapy, but not Prednisone.

5. A client is receiving treatment with capecitabine. Which of the following findings should the nurse monitor?

• A. Hyperglycemia
• B. Hypocalcemia
• C. Neutropenia
• D. Bradycardia

Correct answer: C

Rationale: The nurse should monitor the client for neutropenia when receiving capecitabine, as it is a common adverse effect caused by bone marrow suppression. Neutropenia increases the risk of infection, making it essential for the nurse to closely monitor the client's white blood cell count and assess for signs of infection during treatment. Hyperglycemia (Choice A) is not typically associated with capecitabine. Hypocalcemia (Choice B) and bradycardia (Choice D) are not commonly linked to capecitabine use. Therefore, monitoring for neutropenia is the priority in this scenario.

Similar Questions